Acquired von Willebrand Syndrome Associated with Hypothyroidism: A Mild Bleeding Disorder to Be Further Investigated

ABSTRACT

Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those for congenital von Willebrand disease (VWD). Unlike VWD, AVWS usually occurs in individuals with no personal or family history of bleeding. The prevalence of AVWS in the general population is unknown because data from large prospective studies of this syndrome are not available. Although AVWS is more frequently associated with lympho-myeloproliferative and cardiovascular disorders, it can also occur in solid tumors and in immunological and other miscellaneous conditions. Among these miscellaneous conditions, hypothyroidism has been associated with AVWS type 1 with a frequency of ∼2 to 5%. In the 47 cases reported in the literature, the low VWF is apparently due to a reduction in its synthesis and/or secretion. Diagnosis of AVWS is based on assays measuring the level and activity of von Willebrand factor (VWF). These tend to be low, whereas factor VIII (FVIII) coagulant activity can be normal. In patients with AVWS associated with hypothyroidism, mucocutaneous bleeding episodes are the most frequent and can be managed with local therapy and/or systemic administrations of antifibrinolytic agents and desmopressin. VWF/FVIII concentrates have been used in only a few patients. The use of thyroid hormones can reverse this abnormality.

Acquired von Willebrand syndrome - defective biosynthesis and/or release - von Willebrand factor - mucosal bleeding - desmopressin - VWF/FVIII concentrates

REFERENCES

• 1 Federici A B. Acquired von Willebrand syndrome: an under- and misdiagnosed bleeding complication in patients with lympho- and myeloproliferative disorders.  Semin Hematol. 2006;  43 ((Suppl 1)) S48-S58
• 2 Simone J V, Cornet J A, Abildgaard C F. Acquired von Willebrand's syndrome in systemic lupus erythematosus.  Blood. 1968;  31 (6) 806-812
• 3 Veyradier A, Jenkins C S, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management.  Thromb Haemost. 2000;  84 (2) 175-182
• 4 Michiels J J, Budde U, van der Planken M, van Vliet H H, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.  Best Pract Res Clin Haematol. 2001;  14 (2) 401-436
• 5 Federici A B, Rand J H, Bucciarelli P on behalf of the Subcommittee on von Willebrand Factor et al. Acquired von Willebrand syndrome: data from an international registry.  Thromb Haemost. 2000;  84 (2) 345-349
• 6 Tiede A, Priesack J, Werwitzke S et al.. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.  J Thromb Haemost. 2008;  6 (4) 569-576
• 7 Manfredi E, van Zaane B, Gerdes V EA, Brandjes D P, Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review.  Haemophilia. 2008;  14 (3) 423-433
• 8 Mohri H, Motomura S, Kanamori H et al.. Clinical significance of inhibitors in acquired von Willebrand syndrome.  Blood. 1998;  91 (10) 3623-3629
• 9 Federici A B. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?.  J Thromb Haemost. 2008;  6 (4) 565-568
• 10 Mannucci P M, Lombardi R, Bader R et al.. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.  Blood. 1984;  64 (3) 614-621
• 11 Baumgartner-Parzer S M, Wagner L, Reining G et al.. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells.  J Endocrinol. 1997;  154 (2) 231-239
• 12 Diekman M JM, Zandieh Doulabi B, Platvoet-Ter Schiphorst M, Fliers E, Bakker O, Wiersinga W M. The biological relevance of thyroid hormone receptors in immortalized human umbilical vein endothelial cells.  J Endocrinol. 2001;  168 (3) 427-433
• 13 van Genderen P JJ, Boertjes R C, van Mourik J A. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.  Thromb Haemost. 1998;  80 (3) 495-498
• 14 Mannucci P M, Federici A B. Antibodies to von Willebrand factor in von Willebrand disease. In:, Aledort L M, Hoyer L W, Reisner H M, White II G C, eds. Inhibitors to Coagulation Factors. New York, NY: Plenum Press; 1995: 87-92
• 15 Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome.  Haemophilia. 2003;  9 (3) 303-308
• 16 Federici A B, Stabile F, Castaman G, Canciani M T, Mannucci P M. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.  Blood. 1998;  92 (8) 2707-2711
• 17 Friederich P W, Wever P C, Briët E, Doorenbos C J, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.  Am J Hematol. 2001;  66 (4) 292-294
• 18 Smith S R, Auger M J, MacCallum P K. Hypothyroidism and von Willebrand's disease.  Lancet. 1987;  1 (8545) 1314-1315
• 19 Takahashi H, Yamada M, Shibata A. Acquired von Willebrand's disease in hypothyroidism.  Thromb Haemost. 1987;  58 (4) 1095
• 20 Blesing N E, Hambley H, McDonald G A. Acquired von Willebrand's disease and hypothyroidism: report of a case presenting with menorrhagia.  Postgrad Med J. 1990;  66 (776) 474-476
• 21 Franchini M, Veneri D, Lippi G. Analysis of thyroid hormone status in 131 consecutive individuals with low von Willebrand factor levels.  Haemophilia. 2002;  8 142-144
• 22 Franchini M, Zugni C, Veneri D et al.. High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery.  Haematologica. 2004;  89 (11) 1341-1346
• 23 Tani Y, Morita M, Noguchi S. Prevalence of prolonged APTT and lupus anticoagulant in autoimmune thyroid disease [in Japanese].  Rinsho Byori. 1997;  45 (9) 899-902
• 24 Coccia M R, Barnes H V. Hypothyroidism and acquired von Willebrand disease.  J Adolesc Health. 1991;  12 (2) 152-154
• 25 Levesque H, Borg J Y, Colange T et al.. Willebrand's syndrome in association with hypothyroidism. Prospective study in 12 patients.  Rev Med Interne. 1992;  13 ((Suppl 3)) S188
• 26 Bruggers C S, McElligott K, Rallison M L. Acquired von Willebrand disease in twins with autoimmune hypothyroidism: response to desmopressin and L-thyroxine therapy.  J Pediatr. 1994;  125 ((6 Pt 1)) 911-913
• 27 Attivissimo L A, Lichtman S M, Klein I. Acquired von Willebrand's syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism.  Thyroid. 1995;  5 (5) 399-401
• 28 Nitu-Whalley I C, Lee C A. Acquired von Willebrand syndrome—report of 10 cases and review of the literature.  Haemophilia. 1999;  5 (5) 318-326
• 29 Michiels J J, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.  Clin Appl Thromb Hemost. 2001;  7 (2) 113-115
• 30 Setian N, Tanaka C M, Damiani D, Dichtchekenian V, Carneiro J D, D'Amico E A. Hypopituitarism, deficiency of factors V and VIII and von Willebrand factor: an uncommon association.  J Pediatr Endocrinol Metab. 2002;  15 (3) 331-333
• 31 Concha R, Borzone M A, Castillo M, Rossle A, Quevedo I. [Acquired von Willebrand disease as an unusual manifestation of primary hypothyroidism: report of two cases [in Spanish].  Rev Med Chil. 2005;  133 (7) 813-816
• 32 Erfurth E MT, Ericsson U BC, Egervall K, Lethagen S R. Effect of acute desmopressin and of long-term thyroxine replacement on haemostasis in hypothyroidism.  Clin Endocrinol (Oxf). 1995;  42 (4) 373-378
• 33 Franchini M, de Gironcoli M, Lippi G et al.. Efficacy of desmopressin as surgical prophylaxis in patients with acquired von Willebrand disease undergoing thyroid surgery.  Haemophilia. 2002;  8 (2) 142-144